Business
Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the Company's Next Moves
Cardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the Company's Next Moves.
About this update from Fluoropharma Medical Inc
[{"type":"text","content":"\nCardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the Company's Next Moves \n\nCardiology Product Potential, Clinical Trial Progress and Capital Acquisition Success Drive the Company's Next Moves\n\nMONTCLAIR, NJ--(Marketwired - October 23, 2015) - FluoroPharma Medical, Inc. (OTCQB: FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of cardiovascular disease, announced today the release of a company overview as presented by FluoroPharma's Chairman & CEO, Thijs Spoor, and its President, Thomas Tulip, PhD.Mr. Spoor began, \"I'm very pleased to provide this 'State of the Union' update to our shareholders. The fundamentals for PET cardiac imaging remain strong, with the global isotope market expected to reach $4.5 billion in 2015. Recent reports project that the market could approach $7 billion by 2020, and the need for better diagnostic imaging tools for cardiologists remains unchanged. Cardiovascular procedures and operations increased 28% in the decade between 2000 and 2010, and the challenges and costs of managing cardiovascular disease continue to grow. Myocardial perfusion imaging is still the most frequently used nuclear medicine procedure in the U.S., while the use of PET technology continues to increase in the U.S., Europe and Asia. The recognition of PET's unique potential in imaging cardiovascular disease and uncertainty in the global supply chain for Molybdenum-based SPECT procedures beyond 2016 have increased the expectations for PET cardiac imaging.\"He continued, \"We're encouraged by the progress made to date with the completion of a CardioPET Phase II study, and are confident in the imminent start and rapid recruitment for the BFPET Phase II trial in the U.S. With recent success in the acquisition of investment capital, we are prepared to take the next important steps to enhance shareholder value.\" Mr. Spoor provided a detailed review of key milestones achieved recently:Efforts to secure investment capital have been successful. Spoor stated, \"The environment for small-cap companies has been challenging, but the PET story remains compelling to investors. The fundamental needs in cardiology patient management haven't changed, and the issues are...